Roche’ Herceptin Receives European Approval
The approval is based on the positive results from the international ToGA trial, which showed that treatment with Herceptin prolongs the lives of patients with this aggressive cancer.
The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a 17p deletion.